lunes, 27 de agosto de 2018

Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score. - PubMed - NCBI

Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score. - PubMed - NCBI



 2018 Aug 21. doi: 10.1002/jmri.26244. [Epub ahead of print]

Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.

Abstract

BACKGROUND:

Oncotype Dx is a validated genetic analysis that provides a recurrence score (RS) to quantitatively predict outcomes in patients who meet the criteria of estrogen receptor positive / human epidermal growth factor receptor-2 negative (ER+/HER2-)/node negative invasive breast carcinoma. Although effective, the test is invasive and expensive, which has motivated this investigation to determine the potential role of radiomics.

HYPOTHESIS:

We hypothesized that convolutional neural network (CNN) can be used to predict Oncotype Dx RS using an MRI dataset.

STUDY TYPE:

Institutional Review Board (IRB)-approved retrospective study from January 2010 to June 2016.

POPULATION:

In all, 134 patients with ER+/HER2- invasive ductal carcinoma who underwent both breast MRI and Oncotype Dx RS evaluation. Patients were classified into three groups: low risk (group 1, RS <18), intermediate risk (group 2, RS 18-30), and high risk (group 3, RS >30).

FIELD STRENGTH/SEQUENCE:

1.5T and 3.0T. Breast MRI, T1 postcontrast.

ASSESSMENT:

Each breast tumor underwent 3D segmentation. In all, 1649 volumetric slices in 134 tumors (mean 12.3 slices/tumor) were evaluated. A CNN consisted of four convolutional layers and max-pooling layers. Dropout at 50% was applied to the second to last fully connected layer to prevent overfitting. Three-class prediction (group 1 vs. group 2 vs. group 3) and two-class prediction (group 1 vs. group 2/3) models were performed.

STATISTICAL TESTS:

A 5-fold crossvalidation test was performed using 80% training and 20% testing. Diagnostic accuracy, sensitivity, specificity, and receiver operating characteristic (ROC) area under the curve (AUC) were evaluated.

RESULTS:

The CNN achieved an overall accuracy of 81% (95% confidence interval [CI] ± 4%) in three-class prediction with specificity 90% (95% CI ± 5%), sensitivity 60% (95% CI ± 6%), and the area under the ROC curve was 0.92 (SD, 0.01). The CNN achieved an overall accuracy of 84% (95% CI ± 5%) in two-class prediction with specificity 81% (95% CI ± 4%), sensitivity 87% (95% CI ± 5%), and the area under the ROC curve was 0.92 (SD, 0.01).

DATA CONCLUSION:

It is feasible for current deep CNN architecture to be trained to predict Oncotype DX RS.

LEVEL OF EVIDENCE:

4 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2018.

PMID:
 
30129697
 
DOI:
 
10.1002/jmri.26244

No hay comentarios:

Publicar un comentario